Finding Balance: New Strategies to Optimize Care for Patients With Parkinson's Disease Psychosis
NeurologyParkinson's Disease Psychosis
1 AMA PRA Category 1 Credit(s) ™
October 31, 2017
The accreditation for this activity has expired.
Primary Audience:
This activity has been designed to meet the educational needs of neurologists and psychiatrists.
Relevant Terms:
Parkinson's Disease, Parkinson's Disease Psychosis, Parkinson's Disease Nonmotor Symptoms, Parkinson's Disease Hallucinations,
Jennifer G. Goldman, MD, MS
PDP CURRICULUM PLANNING COMMITTEE Jennifer G. Goldman, MD, MS
Associate Professor
Section of Parkinson's Disease and Movement Disorders
Department of Neurological Sciences
Rush University Medical Center
Chicago, Illinois
Bio
Associate Professor
Section of Parkinson's Disease and Movement Disorders
Department of Neurological Sciences
Rush University Medical Center
Chicago, Illinois
Daniel Weintraub, MD
Daniel Weintraub, MD
Professor of Psychiatry and Neurology
Perelman School of Medicine at the University of Pennsylvania
Parkinson's Disease and Mental Illness
Research, Education and Clinical Centers (PADRECC and MIRECC)
Corporal Michael J. Crescenz Department of Veterans Affairs Medical Center
Philadelphia Veterans Affairs Medical Center
Philadelphia, Pennsylvania
Bio
| 1. | Assess patients for PDP symptoms to facilitate appropriate referral and treatment | 2. | Discuss the clinical features and risk factors for PDP |
| 3. | Develop individualized pharmacologic treatment plans for patients with PDP that consider motor and nonmotor symptoms | 4. | Evaluate the mechanism of action, safety, and efficacy of current pharmacologic treatment options for PDP |
| 5. | Employ multidisciplinary communication strategies to improve quality of life in patients with PDP |
| 1. | Assess patients for PDP symptoms to facilitate appropriate referral and treatment |
| 2. | Discuss the clinical features and risk factors for PDP |
| 3. | Develop individualized pharmacologic treatment plans for patients with PDP that consider motor and nonmotor symptoms |
| 4. | Evaluate the mechanism of action, safety, and efficacy of current pharmacologic treatment options for PDP |
| 5. | Employ multidisciplinary communication strategies to improve quality of life in patients with PDP |
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and MedEdicus LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty/PDP Curriculum Planning Committee reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Jennifer G. Goldman, MD, MS, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Contracted Research: ACADIA Pharmaceuticals Inc; and Biotie Therapies; Consulting Fees (e.g., advisory boards): ACADIA Pharmaceuticals Inc; and Pfizer Inc.
Neal Hermanowicz, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consulting Fees (e.g., advisory boards): ACADIA Pharmaceuticals Inc; and Teva Pharmaceutical Industries Ltd; Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers' bureaus): ACADIA Pharmaceuticals Inc; Allergan; and UCB SA.
Michael S. Okun, MD, has no real or apparent conflicts of interest to report.
Daniel Weintraub, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consulting Fees (e.g., advisory boards): ACADIA Pharmaceuticals Inc.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Jan Schultz, RN, MSN, CHCP, and Judi Smelker-Mitchek, RN, BSN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following MedEdicus planners and managers, Diane McArdle, PhD, Leslie Sharp, and Cynthia Tornallyay, RD, MBA, CHCP, have no real or apparent conflicts of interest to report.
Method of Participation and Request for Credit
There are no fees for participating in and receiving CME credit for this activity. During the period 10/31/17, through 10/31/18, participants must read the learning objectives and faculty disclosures and study the educational activity. Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, a certificate will be made available immediately.
Disclosure of Unlabeled Use
This educational activity might contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Media
Internet
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |
